Clinical Trials Study
Copyright ©The Author(s) 2024.
World J Clin Cases. Jul 16, 2024; 12(20): 4191-4198
Published online Jul 16, 2024. doi: 10.12998/wjcc.v12.i20.4191
Table 1 Results of medication adherence rate
Indicator
Observation, n = 57
Control, n = 57
t/χ2
P value
Full compliance28 (49.12)21 (36.84)NANA
Partial compliance24 (42.11)22 (38.60)NANA
Non-compliance5 (8.77)14 (24.56)NANA
Total compliance rate52 (91.23)43 (75.44)5.1160.024
Table 2 Results of disease awareness score
Indicators
Before intervention
After intervention
Observation, n = 5761.35 ± 3.5486.82 ± 4.27
Control, n = 5761.74 ± 4.8470.86 ± 3.95
t0.48620.720
P value0.628< 0.001
Table 3 Results of medication safety
Indicators
Observation, n = 57
Control, n = 57
t/χ2
P value
Gastrointestinal reaction9 (15.79)20 (35.09)5.5960.018
Joint swelling and pain7 (12.28)16 (28.07)4.4120.036
Hearing loss4 (7.02)12 (21.05)4.6530.031
Electrolyte disturbance1 (1.75)2 (3.51)0.4220.516
Liver and kidney dysfunction3 (5.26)10 (17.54)4.2540.039
Table 4 Comparison of results by PCR-capillary electrophoresis and immunohistochemistry
Indicators
Observation, n = 57
Control, n = 57
t/χ2
P value
Satisfied30 (52.63)25 (43.86)NANA
Generally satisfied20 (35.09)10 (17.54)NANA
Not satisfied7 (12.28)22 (38.60)NANA
Total satisfaction50 (87.72)35 (61.40)10.4060.001